Serum apolipoprotein C‐III in high‐density lipoprotein: a key diabetogenic risk factor in Turks
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aims We studied determinants of serum apolipoprotein C‐III (apoC‐III) and whether levels of apoC‐III or its fractions predict metabolic syndrome (MetS), Type 2 diabetes and coronary heart disease (CHD). Methods The predictive value of apoC‐III, measured by immunoturbimetric immunoassay in 802 tracked individuals of a Turkish general population in determining cardiometabolic risk was assessed over 4.4 ± 1.2 years’ follow‐up. Patients with MetS, Type 2 diabetes and CHD at baseline were excluded. Results Total apoC‐III, as well as both fractions, was significantly, linearly and inversely related to smoking status, positively to alcohol usage and to levels of complement C3. Mid and high tertiles of total or non‐high density lipoprotein (HDL) apoC‐III predicted significantly and independently incident MetS; they predicted CHD with risk ratios of 1.6 [95% confidence intervals (CI) 1.02–2.5], for 1 sd increment, after adjustments that included HDL cholesterol and body mass index (BMI). The highest tertile of HDL apoC‐III was a major independent predictor of new‐onset diabetes with a 2.5‐fold risk ratio for 1 sd increment (95% CI 1.5–4.0) in combined sexes, after adjustment for waist circumference, HDL cholesterol and other confounders and was a better predictor than waist girth. Conclusions Serum total apoC‐III or its fractions are linearly and inversely associated with smoking, positively with alcohol usage and serum complement C3. The presumably dysfunctional HDL apoC‐III is a stronger predictor of Type 2 diabetes than waist girth in Turks. Non‐HDL apoC‐III predicts strongly the development of MetS as well as incident CHD, independent of HDL cholesterol, BMI and non‐lipid factors. The atherogenicity of apoC‐III and dysfunctionality of HDL apoC‐III carry huge public health implications in Turks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410
Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P. (1990) · Circulation · doi:10.1161/01.cir.81.2.470 · Cited by 278
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
Olivieri, O., Bassi, A., Stranieri, C., Trabetti, E., Martinelli, N., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., & Corrocher, R. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300253-jlr200 · Cited by 139
Onat, A., Hergenç, G., Sansoy, V., Fobker, M., Ceyhan, K., Toprak, S., & Assmann, G. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00025-x · Cited by 134
Self-citationLuc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37594-5 · Cited by 114
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113
Apolipoprotein CIII links dyslipidemia with atherosclerosis
Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98
Cited by
Onat, A., Can, G., Kaya, H., & Hergenç, G. (2010) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2010.02.005 · Cited by 421
Self-citationApolipoproteins: metabolic role and clinical biochemistry applications
Dominiczak, M. H., & Caslake, M. J. (2011) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011111 · Cited by 238
Huth, C., von Toerne, C., Schederecker, F., de las Heras Gala, T., Herder, C., Kronenberg, F., Meisinger, C., Rathmann, W., Koenig, W., Waldenberger, M., et al. (2019) · European Journal of Epidemiology · doi:10.1007/s10654-018-0475-8 · Cited by 56
Apolipoprotein status in type 2 diabetes mellitus and its complications
Zhang, P., Gao, J., Pu, C., & Zhang, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7831 · Cited by 55
“…kinase 3), abnormal protein expression (tumor necrosis factor-a, interleukin-6, retinol binding protein 4 and soluble cluster of differentiation 36), and phosphorylation of multiple pathways components (insulin receptor substrate 2/Akt protein/protein tyrosine phosphatase‑1B) related to…”
Metadata
- Authors
- Onat, A., Hergenç, G., Ayhan, E., Uğur, M., Kaya, H., Tuncer, M., & Can, G.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2009-09-25
- Volume
- 26
- Issue
- 10
- Pages
- 981-988
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2006241476
- Cited by
- 55
- References
- 9
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum apolipoprotein C‐III in high‐density lipoprotein: a key diabetogenic risk factor in Turks. https://app.cochat.ai/papers/10.1111/j.1464-5491.2009.02814.x
- The paper
- Onat, A., Hergenç, G., Ayhan, E., Uğur, M., Kaya, H., Tuncer, M., & Can, G. (2009). Serum apolipoprotein C‐III in high‐density lipoprotein: a key diabetogenic risk factor in Turks. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2009.02814.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.